Immunology Biopharmaceutical

Biopharmaceuticals
Immunology Biopharmaceutical
Trade Of The Day

Top BioPharma Stock To Buy Now

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem […]

Read More
Biopharmaceuticals
Cancer Biopharmaceuticals
Immunology Biopharmaceutical
Value Investing
Value Stocks

GILD is down about -15% since the end of 2022. Is it a good bargain yet?

No matter how much the world moves away from COVID-19, the truth is that it isn’t going away. The move by government entities as well as healthcare organizations around the world to “endemic” phase protocols doesn’t mean the disease has been eradicated. It really means that the disease is acknowledged as a permanent part of […]

Read More
Biopharmaceuticals
Immunology Biopharmaceutical
Pharmaceuticals
Value Investing
Value Stocks

GILD is near its 52-week high. Where is its bargain price?

No matter how tired we get of hearing about COVID-19, the truth is that it hasn’t gone away, and neither have the health concerns associated with it. There is no denying that ever since the virus found its way to American shores almost three years ago, a lot of media attention has been given to […]

Read More
Biomedical
Biopharmaceuticals
Immunology Biopharmaceutical
Immunotherapies
Stock Market Today
Top Stock Market News

Stock Market Update – Bullish Pause – BioMed Stock Moving

Market conditions are Mildly bullish in a Bear Market as of 2022-11-28. This means traders and investors should consider trading with a Neutral or Bullish bias by buying stocks and setting tight stops. The rank of the Bear Market is -16.70 which indicates the current market conditions are Extreme, Risk of a reversal is high. […]

Read More
Biopharmaceuticals
Biotech
COVID-19
Dividend Stocks
Dividends
Fibonacci Retracement
Fundamental Analysis
Immunology Biopharmaceutical
Large Cap
Pharmaceuticals
Technical Analysis
Vaccines
Value Investing
Value Stocks

JNJ is stabilizing after dropping off a 52-week high – is it a good buy?

Years ago, as I began my career as an investor, I read a book by Peter Lynch. Mr. Lynch had made his name, and his fortune, as the manager of Fidelity’s flagship Magellan fund in the late 70’s and ’80’s, and his incredible performance was one of the big reasons Magellan, at the time, was […]

Read More
Biotech
Cancer
Cancer Biopharmaceuticals
Coronavirus
COVID-19
Dividends
Economy
Fibonacci Retracement
Fundamental Analysis
HeathCare
Immunology Biopharmaceutical
Immunotherapies
Pharmaceuticals
RNA Biotechnology
Technical Analysis
Tumor-Specific Cancer Immunotherapies
Vaccines
Value Investing
Value Stocks

PFE is down about 20% in the last three months, and that’s a good thing for value-focused investors

As recently as a few months ago, a lot of signs about the global pandemic seemed to suggest that the worst of the worst was over, and we could all finally begin to put COVID-19 concerns and commentary in the rear view. As contagious variants of the virus have emerged, however, it has become more […]

Read More
Automotive Retail
Daily Rundown
Digital Media
Genetically Defined Diseases
Immunology Biopharmaceutical
Property and Casualty Reinsurance

Genetically Defined Diseases, Digital Media, Property and Casualty Reinsurance, Automotive Retail, Immunology Biopharmaceutical

Fulcrum Therapeutics, Inc. (FULC) Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment […]

Read More
X